Lantheus (NASDAQ:LNTH) Hits New 12-Month High – Here’s What Happened

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $111.52 and last traded at $111.2550, with a volume of 83991 shares traded. The stock had previously closed at $109.58.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of research reports. William Blair reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Citizens Jmp reiterated a “market outperform” rating and issued a $115.00 target price on shares of Lantheus in a report on Monday. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. Finally, Truist Financial reiterated a “buy” rating and set a $115.00 target price (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Performance

The business has a 50-day moving average of $96.39 and a two-hundred day moving average of $80.34. The company has a market cap of $7.20 billion, a P/E ratio of 26.68 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm’s revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently bought and sold shares of LNTH. Empowered Funds LLC acquired a new stake in Lantheus in the first quarter valued at approximately $909,000. Carmignac Gestion lifted its holdings in shares of Lantheus by 18.4% during the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock valued at $100,729,000 after purchasing an additional 206,000 shares during the last quarter. Defilade Capital Management L.P. purchased a new stake in shares of Lantheus during the 1st quarter valued at $18,917,000. Parallel Advisors LLC boosted its position in shares of Lantheus by 95.9% in the 1st quarter. Parallel Advisors LLC now owns 1,060 shares of the medical equipment provider’s stock worth $80,000 after purchasing an additional 519 shares in the last quarter. Finally, Allen Capital Group LLC purchased a new position in Lantheus during the 1st quarter worth $250,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.